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MaOBJECTIVES This study sought to examine the prevalence and predictors of inﬂuenza vaccination among participants
in the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity
in Heart Failure) study and investigate associations between receiving inﬂuenza vaccine and cardiovascular death or heart
failure hospitalizations, all-cause hospitalizations, and cardiopulmonary or inﬂuenza-related hospitalizations.
BACKGROUND Inﬂuenza is associated with an increased risk for cardiovascular events in patients with heart failure.
METHODS We used data from the PARADIGM-HF trial in which patients with heart failure were randomized to the
angiotensin receptor neprilysin inhibitor LCZ696 (sacubitril/valsartan) or enalapril. We assessed predictors of receiving
inﬂuenza vaccination, and examined the relationship between inﬂuenza vaccination and outcomes in a propensity-
adjusted model.
RESULTS Of 8,099 study participants, 1,769 (21%) received inﬂuenza vaccination. We observed signiﬁcant regional
variation in vaccination rates, with highest rates in the Netherlands (77.5%), Great Britain (77.2%), and Belgium (67.5%),
and lowest rates in Asia (2.6%), with intermediate rates in North America (52.8%). Top predictors of vaccination included
enrolling country, white race, implanted deﬁbrillator, older age, lower New York Heart Association functional class, lower
heart rate, and a history of diabetes mellitus. Inﬂuenza vaccination was associated with a reduced risk for all-cause
mortality in propensity-adjusted (hazard ratio: 0.81; 95% conﬁdence interval: 0.67 to 0.97; p ¼ 0.015) models.
CONCLUSIONS Inﬂuenza vaccination rates varied widely in patients with heart failure with reduced ejection fraction
enrolled in the PARADIGM-HF trial, and vaccination was associated with reduced risk for death, although whether this
association was causal cannot be determined. (J Am Coll Cardiol HF 2016;4:152–8) © 2016 by the American College of
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AB BR E V I A T I O N S
AND ACRONYM S
eGFR = estimated glomerular
ﬁltration rate
GDP = gross domestic product
NYHA = New York Heart
Association
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153I nﬂuenza infection can be devastating for patientswith cardiovascular disease, and leads to signiﬁ-cant morbidity and mortality each year (1–4).
Inﬂuenza vaccination is recommended annually for
patients with cardiovascular disease by both the Cen-
ters for Disease Control and Prevention, the American
Heart Association, and the EuropeanCenter for Disease
Prevention and Control (5,6). A meta-analysis of ran-
domized, controlled studies has shown that receiving
inﬂuenza vaccination reduced the risk for major
adverse cardiovascular events in patients with coro-
nary artery disease compared to no vaccination (7).
Although widely recognized as beneﬁcial, vacci-
nation rates in patients with heart failure vary
signiﬁcantly in the United States and across the world
(8). Heart failure patients are especially susceptible to
inﬂuenza-related complications including acute heart
failure exacerbations and secondary infections such
as pneumonia, both of which increase hospitaliza-
tions (4,9).SEE PAGE 159The PARADIGM-HF (Prospective Comparison of
ARNI with ACEI to Determine Impact on Global
Mortality and Morbidity in Heart Failure) trial (10)
enrolled patients with symptomatic heart failure
with reduced ejection fraction and randomly allo-
cated them to receive the angiotensin receptor
neprilysin inhibitor LCZ696 (sacubitril/valsartan) or
enalapril. At the time of enrollment, participants
were queried about receipt of inﬂuenza vaccination in
the past 12 months. We used data from PARADIGM-
HF to assess prevalence of and baseline factors
associated with inﬂuenza vaccination, as well as
outcomes in those who did and did not receive
inﬂuenza vaccination. We hypothesized that inﬂu-
enza vaccination would be associated with reduced
risk for hospitalizations and mortality in patients
with heart failure after propensity adjustment.
METHODS
STUDY DESIGN AND PATIENT SELECTION. The
PARADIGM-HF trial was a double blind, randomized,
active controlled trial designed to assess the impact of
the angiotensin receptor neprilysin inhibitor LCZ696
(sacubitril/valsartan) compared with enalapril on
cardiovascular mortality and heart failure hospitali-
zations in patients with left ventricular ejection
fraction #40% and New York Heart Association
(NYHA) functional class II to IV heart failure. Eligible
subjects had elevated natriuretic peptide levels and
were treated with stable doses of angiotensin-
converting enzyme inhibitors or angiotensin receptorblockers and beta-adrenergic receptor
blockers for at least 4 weeks prior to trial
enrollment. Patients with symptomatic hypo-
tension, estimated glomerular ﬁltration rate
(eGFR) <30 ml/min/1.73m2, potassium con-
centration>5.2mmol/l at screening, or history
of angioedema were excluded. The study
design and detailed inclusion and exclusion
criteria have been previously reported (11).
Participants underwent 2 back-to-back single blind
run-in phases with enalapril at a dose of at least 10 mg
twice daily for 2weeks, followed by LCZ696 (sacubitril/
valsartan), ﬁrst dosed at 100 mg twice daily, then 200
mg twice daily for 4 to 6 weeks. Participants were then
randomized to receive enalapril 10 mg twice daily or
LCZ696 (sacubitril/valsartan) 200 mg twice daily. Par-
ticipants were followed for a median duration of
27months. Participants were asked if they received the
seasonal inﬂuenza vaccine during the previous 12
months, and this information was recorded in the case
report form. Cardiopulmonary and inﬂuenza-related
hospitalizations were captured through investigator
reporting of cause of hospitalization on the case report
form. The protocol was approved at each participating
site by an ethics committee or institutional review
board. All participants provided written informed
consent in accordance with established guidelines
for the protection of human subjects.
STATISTICAL ANALYSES. In order to identify po-
tential differences, baseline characteristics were
compared between participants who received inﬂu-
enza vaccination and those who did not. Between-
group assessments were performed using t tests for
continuous variables, and chi-square or Fisher’s exact
tests, as appropriate, for categorical variables. Logis-
tic regression models were used to examine associa-
tions between baseline characteristics and receipt of
inﬂuenza vaccination, adjusting for treatment
assignment and the following covariates: age, sex,
race, country, body mass index, ejection fraction,
eGFR, NYHA functional class, history of diabetes
mellitus, myocardial infarction, respiratory disease,
and use of angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers, beta-adrenergic
blockers, mineralocorticoid receptor antagonists,
and diuretics at screening. A propensity score was
created for receipt of inﬂuenza vaccination based on
the logistic regression model. For the analysis of
multivariable predictors of vaccination, country was
included as a continuous covariate, represented by
the observed overall vaccination rate of each partici-
pant’s home country, rather than country on its own.
As an exploratory analysis, we used each country’s per-
capita gross domestic product (GDP) as a continuous
TABLE 1 Baseline Characteristics by Inﬂuenza Vaccine Use
No Inﬂuenza
Vaccination
(n ¼ 6,630; 79%)
Inﬂuenza
Vaccination
(n ¼ 1,769; 21%) p Value
Age, yrs 62.7  11.5 67.9  10.1 <0.0001
Female, % 1,481 (22.3) 351 (19.8) 0.024
Caucasian 4,008 (60.5) 1,536 (86.8) <0.0001
Body mass index, kg/m2 27.93  5.50 29.06  5.51 <0.0001
Ischemic etiology 3,949 (59.6) 1,087 (61.4) 0.15
NYHA functional class <0.0001
I 306 (4.6) 83 (4.7)
II 4,569 (69.0) 1,350 (76.5)
III 1,694 (25.6) 324 (18.4)
IV 52 (0.8) 8 (0.5)
Left ventricular ejection
fraction
29.53  6.17 29.32  6.41 0.1968
History of heart failure
hospitalization
4,267 (64.4) 1,007 (56.9) <0.0001
History of hypertension 4,722 (71.2) 1,218 (68.9) 0.052
History of diabetes 2,184 (32.9) 723 (40.9) <0.0001
History of myocardial
infarction
2,761 (41.6) 873 (49.3) <0.0001
Use of ICD 667 (10.1) 576 (32.6) <0.0001
Use of CRT 305 (4.6) 269 (15.2) <0.0001
Baseline medications
ACE inhibitors 5,120 (77.2) 1,412 (79.8) 0.02
ARBs 1,519 (22.9) 373 (21.1) 0.10
Beta-blockers 6,139 (92.6) 1,672 (94.5) 0.005
MRAs 3,817 (57.6) 854 (48.3) <0.0001
Diuretic 5,307 (80.0) 1,431 (80.9) 0.43
Digoxin 2,100 (31.7) 439 (24.8) <0.0001
eGFR 69.5  19.5 63.1  17.9 <0.0001
NT-proBNP 1,638 (897–3,350) 1,569 (870–2.945) 0.08
Values are mean  SD, n (%), or median (Interquartile range).
ACE ¼ angiotensin-converting enzyme; ARBs ¼ angiotensin receptor blockers; CRT ¼ cardiac
resynchronization therapy; eGFR ¼ estimated glomerular ﬁltration rate; ICD ¼ implantable
cardioverter-deﬁbrillator; MRAs ¼ mineralocorticoid receptor antagonists; NT-proBNP ¼
N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association.
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154variable in the multivariable model. Cox proportional
hazards models were constructed to investigate
associations of inﬂuenza vaccination with the risk
for all-cause mortality, cardiovascular death or heart
failure hospitalization, all-cause hospitalizations,
and cardiopulmonary or inﬂuenza-related hospitali-
zations, in unadjusted as well as propensity-matched
models. The propensity models were implemented
by creating 100 equally sized groups of patients based
on their estimated propensity for having received
inﬂuenza vaccination, as described previously. These
groups were subsequently used as a stratiﬁcation fac-
tor in the Coxmodel, so that the reported hazard refers
to the comparison of vaccinated and unvaccinated
patients within the same propensity stratum. We per-
formed a sensitivity analysis examining the associa-
tion of inﬂuenza vaccine receipt and clinical outcomes,
censoring events at 12months because we did not have
data on vaccination after randomization. A p valueof <0.05 was considered statistically signiﬁcant. All
analyses were completed using Stata, version 13 (Sta-
taCorp LP, College Station, Texas).
RESULTS
Of 8,399 participants in the PARADIGM-HF trial, 1,769
(21%) received inﬂuenza vaccination within a
12-month period while enrolled in the study. Baseline
characteristics by inﬂuenza vaccination status are
shown in Table 1. Inﬂuenza vaccine recipients were
signiﬁcantly older, had higher body mass index, lower
NYHA functional class and eGFR, and were more
likely to be male and Caucasian. More vaccine re-
cipients had a history of diabetes, myocardial infarc-
tion, were taking beta-blockers, and had received
cardiac resynchronization therapy, and less were
taking mineralocorticoid receptor antagonists. There
was signiﬁcant variation in vaccination rates by
country, with vaccination rates highest in the
Netherlands (77.5%) the United Kingdom (77.2%), and
Belgium (67.5%), and lowest in Asia (2.6%) (Table 2).
In a multivariable regression model, signiﬁcant
predictors of receiving inﬂuenza vaccine included, in
descending order of association: country, older age,
history of diabetes mellitus, lower NYHA functional
class, lower heart rate, use of digoxin, use of an
implantable cardioverter-deﬁbrillator or cardiac
resynchronization therapy, lower eGFR, higher ejec-
tion fraction, white race, and history of hospitalization
for heart failure (Table 3). In an exploratory analysis,
we observed a correlation between vaccination rates
and country-speciﬁc GDP data (Online Figure 1).
Inﬂuenza vaccination was associated with a
lower risk for all-cause mortality compared to no
vaccination in unadjusted models (Figure 1) and after
adjusting for the propensity to receive inﬂuenza
vaccine (hazard ratio: 0.81; 95% conﬁdence interval:
0.67 to 0.97; p ¼ 0.015). In contrast, vaccination was
associated with increased rates of cardiopulmonary,
inﬂuenza-related, and all-cause hospitalization in
unadjusted models, but not in propensity-adjusted
models (Table 4). Sensitivity analyses censoring
events at 12 months post-randomization revealed
similar results (data not shown). The overall beneﬁt
of LCZ696 (sacubitril/valsartan) over enalapril on
the trial’s primary outcome was maintained regard-
less of inﬂuenza vaccination (p for interaction ¼ 0.31).
DISCUSSION
In patients with heart failure and reduced ejection
fraction enrolled in the PARADIGM-HF study, we
found substantial worldwide regional variation in
TABLE 2 Vaccination Rate by Country
Country Percentage
Argentina 30.2
Belgium 67.6
Bulgaria 1.4
Brazil 29.7
Canada 47.0
Chile 44.1
China 0.6
Columbia 7.3
Czechoslovakia 10.0
Germany 37.1
Denmark 54.7
Dominican Republic 0
Ecuador 7.8
Spain 52.8
Estonia 3.4
Finland 60.0
France 39.1
Great Britain 77.2
Guatemala 2.9
Hong Kong 8.7
Hungary 22.7
India 0.2
Iceland 55.6
Israel 36.6
Italy 41.0
Korea 20.7
Lithuania 0
Latvia 0
Mexico 17.5
Malaysia 0
Netherlands 77.5
Panama 13.3
Peru 0
Philippines 4.0
Poland 4.6
Portugal 53.1
Romania 4.4
Russia 0.2
Singapore 9.3
Slovakia 14.3
Sweden 55.2
Thailand 0
Turkey 1.6
Taiwan 5.8
United States 55.1
Venezuela 0
South Africa 6.2
TABLE 3 Predictors of Receipt of Inﬂuenza Vaccine
Predictor* z-Score Odds Ratio (95% CI)
Country 31.8 1.79 (1.72–1.85)
Age 7.32 1.02 (1.02–1.04)
History of diabetes mellitus 4.16 1.35 (1.17–1.55)
NYHA functional class 3.38 0.79 (0.68–0.90)
Heart rate 2.51 0.99 (0.986–0.998)
Use of digoxin 2.51 1.22 (1.04–1.43)
Use of an ICD 2.37 1.33 (1.02–1.47)
Use of CRT 2.18 1.22 (1.05–1.69)
eGFR 2.18 0.995 (0.992–1.0)
Ejection fraction 2.06 1.01 (1.0–1.02)
White race 2.01 1.21 (1.0–1.45)
History of hospitalization
for heart failure
1.98 0.87 (0.76–1.0)
*Other model covariates which were not signiﬁcant included: history of myocardial
infarction, left ventricular ejection fraction, blood pressure, sex, body mass index,
use of angiotensin-converting enzyme inhibitor, angiotensin receptor blocker,
beta-blocker, magnetic resonance angiography, or diuretic, N-terminal pro–B-type
natriuretic peptide, and B-type natriuretic peptide.
Abbreviations as in Table 1.
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155inﬂuenza vaccination rates, with rates substantially
higher in Western Europe, the United States, and
Canada compared to Asia. However, even in the
United States, despite strong recommendations from
the CDC and a science advisory statement published
by the American Heart Association advocating for
annual vaccination, vaccination rates were only 53%in this high-risk population (5,12). Aside from coun-
try, the most signiﬁcant predictors of vaccination
included older age, history of diabetes mellitus,
lower NYHA functional class, lower heart rate,
use of digoxin, and use of either an implantable
cardioverter-deﬁbrillator or cardiac resynchroniza-
tion therapy. Inﬂuenza vaccination was associated
with lower all-cause mortality even when adjusted
for the propensity to receive inﬂuenza vaccine.
Vaccination did not affect the efﬁcacy of LCZ696
(sacubitril/valsartan).
There are limited data on inﬂuenza vaccination
rates in patients with heart failure worldwide. In
the United States, inﬂuenza vaccination rates in pa-
tients with heart failure have ranged from 25% to
approximately 76%, depending on the population
studied (13–15). In one study of patients with heart
failure who were mostly indigent or had Medicare or
Medicaid, baseline rates were 28.3% prior to a vacci-
nation campaign program, and improved to 50.3%
after the program (14). In an analysis of the impact
of American Heart Association’s Get With The
Guidelines–Heart Failure “Plus” program, which
recognized hospitals for additional quality measures
such as inﬂuenza vaccination, the increase in inﬂu-
enza vaccination rates slowed following program
implementation compared to years leading up to the
program, although baseline vaccination rates were
greater than 50% (13). The reasons for poor inﬂuenza
vaccine uptake in the heart failure population remain
unclear, but include factors such as reduced accessi-
bility to vaccination clinics in rural areas, cost of
FIGURE 1 Crude and Propensity-Adjusted Hazard Ratio for All-Cause Death, Cardiovascular Death or Heart Failure Hospitalization
(Primary Endpoint), All-Cause Hospitalization, and Cardiopulmonary/Inﬂuenza-Related Hospitalization or Death
Inﬂuenza vaccination was associated with a lower risk for all-cause death. In crude, but not propensity adjusted models, inﬂuenza vaccination
was associated with a higher risk for hospitalizations.
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156vaccination if uninsured or if vaccination programs
are not offered through employers, limited knowl-
edge regarding the beneﬁts of vaccination, mistrust
of ingredients contained in the vaccine, or the
misconception that inﬂuenza vaccination will cause
inﬂuenza infection (14,16).
We found that the most important factor inﬂu-
encing vaccination was country. We observed low
vaccination rates among Asian countries as previously
reported, which may be due to factors such as
competing health care priorities and inadequate
resources, particularly in developing countries,
incomplete region-speciﬁc data regarding inﬂuenza
vaccine effectiveness, or differing practice patterns
between regions (17–19). Older age, white race, andTABLE 4 Association Between Inﬂuenza Vaccination
and Outcomes
Outcome
Unadjusted
Propensity
Adjusted
HR 95% CI HR 95% CI
Death 0.81 0.71–0.92 0.82 0.70–0.96
Cardiovascular death or heart
failure hospitalization
0.91 0.81–1.01 0.93 0.81–1.06
Cardiopulmonary or
inﬂuenza-related
hospitalization or death
1.11 1.02–1.20 0.99 0.89–1.10
All-cause hospitalization 1.50 1.39–1.61 1.07 0.97–1.18
CI ¼ conﬁdence interval; HR ¼ hazard ratio.concomitant diabetes mellitus were also signiﬁcant
predictors of vaccination, potentially due to increased
health care utilization or improved access to health
care (20). Country-speciﬁc GDP appeared to be asso-
ciated with per-country vaccination rates, suggesting
that socioeconomic status may play a role in vacci-
nation, although these ﬁndings should be interpreted
with caution, as we did not have participant-speciﬁc
socioeconomic data and these factors can vary
widely within countries.
We found that patients who received inﬂuenza
vaccination had lower all-cause mortality, even when
adjusting for the propensity to receive vaccination.
This ﬁnding is consistent with other observational
studies that have similarly reported lower rates of
death in individuals receiving inﬂuenza vaccination,
including a retrospective analysis of over 100,000
patients with heart failure from the Veterans Health
Administration (15), and a prospective cohort analysis
of patients hospitalized for heart failure (21). Despite
the adjustment for the propensity to receive inﬂuenza
vaccine, the observed association between inﬂuenza
vaccination and lower mortality may simply be indic-
ative of better access to health care, improved sur-
veillance, or ambulatory independence of vaccine
recipients, and does not prove that inﬂuenza vacci-
nation reduces mortality in this population. As we
observed substantial differences between those who
did and did not receive vaccine, we cannot rule out the
possibility that unmeasured confounding for which
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: Inﬂuenza
vaccination is recommended on an annual basis in patients with
heart failure and may be associated with reduced mortality.
COMPETENCY IN MEDICAL KNOWLEDGE 2: Health care
providers should educate patients on the beneﬁts of annual inﬂuenza
vaccinationandprovideopportunities forvaccination inclinicsettings.
TRANSLATIONAL OUTLOOK 1: Future studies should
examine associations between multiple-year inﬂuenza vaccina-
tion and cardiovascular outcomes in patients with heart failure.
TRANSLATIONAL OUTLOOK 2: Although annual inﬂuenza
vaccination is recommended by clinical guidelines, it is not
known which speciﬁc inﬂuenza vaccine (trivalent, high dose,
quadrivalent) may be most beneﬁcial in this high-risk population.
TRANSLATIONAL OUTLOOK 3: The exact mechanisms by
which inﬂuenza vaccination may lead to improved outcomes in
patients with heart failure requires further study.
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157we are not able to adjust may contribute to the
observed ﬁndings among inﬂuenza vaccine recipients.
That inﬂuenza vaccination was associated with a
higher unadjusted rate of hospitalization of any type,
but not an increased risk of death, suggests that in
the PARADIGM-HF trial, inﬂuenza vaccination was
a potential surrogate for higher level of and im-
proved access to health care, evidenced by more
hospitalizations, for any given severity of illness,
among individuals who received inﬂuenza vaccine.
The fact that the risk for hospitalization was sub-
stantially altered following propensity adjustment
implies that factors that inﬂuence the likelihood of
vaccination might also inﬂuence rates of hospitaliza-
tion. Nevertheless, other large, but more geographi-
cally homogenous, observational studies have shown
associations between inﬂuenza vaccination and
reduced risk for hospitalizations (22,23).
STUDY LIMITATIONS. Several additional limitations
of this analysis should be noted. First, we only had
vaccination information during a 12-month period in
the trial, and as such could not examine associations
betweenmultiple year receipt of inﬂuenza vaccination
and clinical outcomes, as these data were not
collected. Inﬂuenza vaccination history was collected
by site personnel via a case report form, and may be
subject to recall bias. Additionally, we did not collect
information about the type of vaccine participants
received (high dose, quadrivalent, adjuvant), there-
fore we were not able to explore whether certain vac-
cine formulations were more strongly associated with
better outcomes. Patients with heart failure exhibited
blunted immune responses to standard dose trivalent
inﬂuenza vaccination in previous studies (24,25), and
use of a higher dose of inﬂuenza vaccine resulted in
enhanced antibody titers compared to a standard
dose formulation (26). However, the vaccine formula-
tion that portends the greatest protection against
inﬂuenza-related complications remains unclear.
CONCLUSION
In a cohort of patients with heart failure and reduced
ejection fraction who were well managed on guidelinedirected medical therapy, we observed signiﬁcant
regional variation in rates of inﬂuenza vaccination,
despite well-publicized recommendations from public
health organizations advocating for annual immuni-
zation in this high-risk population. Recipients of
inﬂuenza vaccination tended to be older and of
Caucasian heritage, and more commonly had other
comorbidities that may necessitate closer medical
follow up. Inﬂuenza vaccination did not affect the ef-
ﬁcacy of LCZ696, but was associated with lower all-
cause mortality, even after adjustment for the pro-
pensity to receive inﬂuenza vaccination, although
whether this association was causal cannot be deter-
mined from these observational data.
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